Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Graves' Disease, Graves Disease
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 29
States / cities: Carlsbad, California • Orange, California • Pasadena, California + 24 more

Conditions: Secondary Progressive Multiple Sclerosis (SPMS)
Interventions: Remibrutinib (blinded), Placebo, Remibrutinib (Open label); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1.5% Cream BID, Triamcinolone 0.1% Cream BID, Vehicle Cream BID; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Birmingham, Alabama • Bryant, Arkansas • Encino, California + 28 more

Conditions: AKI, Contrast-induced Nephropathy
Interventions: Experimental Arm; Other
Lead sponsor: Qure Healthcare, LLC; Industry
Eligibility: Not listed
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Gastrointestinal
Interventions: Synbiotic Dietary Supplement, Placebo; Dietary Supplement
Lead sponsor: OvationLab; Network
Eligibility: 25 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: COVID 19
Interventions: MR or M-M-R II ® vaccine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 3,411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity, Prediabetic State
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco Use Disorder, Smoking
Interventions: Ariva Silver Wintergreen, Placebo Wintergreen; Other
Lead sponsor: Star Scientific, Inc; Industry
Eligibility: 23 Years to 72 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Martinsburg, West Virginia

Conditions: System Lupus Erythematosus(SLE)
Interventions: guided increases in daily walking; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Chlorhexidine irrigation, triple antibiotic irrigation; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 81 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bronchiectasis
Interventions: AZLI, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Florence, Alabama • Flagstaff, Arizona • Peoria, Arizona + 30 more

Conditions: Acute Gastroenteritis, Norwalk Virus Infection
Interventions: Norwalk VLP vaccine, mannitol and sucrose, Norwalk virus; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas

Conditions: Smoking
Interventions: Usual Brand Cigarette, Electronic Cigarette #1, Electronic Cigarette #2, Leading U.S. Nicotine Gum; Other
Lead sponsor: R.J. Reynolds Vapor Company; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Heartburn
Interventions: Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 10
States / cities: Mobile, Alabama • San Francisco, California • Westlake Village, California + 7 more

Conditions: Parents
Interventions: Familia Bora; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 792 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Weight Loss
Interventions: ResArgin; Dietary Supplement
Lead sponsor: Dr. Heather Hausenblaus; Other
Eligibility: 25 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone; Device · Drug
Lead sponsor: Diane George; Other
Eligibility: Up to 22 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Tinnitus, Subjective
Interventions: OTO-313, Placebo; Drug
Lead sponsor: Otonomy, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 13 more

Conditions: Platysma Prominence
Interventions: OnabotulinumtoxinA, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 26
States / cities: Glendale, Arizona • Scottsdale, Arizona • Encino, California + 23 more

Conditions: Aging
Interventions: Mindfulness-Based Stress Reduction (MBSR), Lifestyle Education (LifeEd); Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Respiratory Syncytial Virus Infection
Interventions: Presatovir, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Duarte, California • Chicago, Illinois • Baltimore, Maryland + 8 more

Conditions: Obesity
Interventions: BMF-650; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Generalized Myasthenia Gravis
Interventions: IMVT-1402, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 48
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more

Conditions: Alzheimer's Disease
Interventions: Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo, Donepezil; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 1,496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 41
States / cities: Litchfield Park, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 36 more

Search by objective public record fields.

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization

Terraflora Daily Care and Gastrointestinal Health

CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION

Effect of Melatonin on Cardiometabolic Risk- FULL

A Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge

Lupus Walking Intervention to Address Fatigue/Quality of Life

Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

Norwalk Vaccine Study

Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum

Efficacy of Esomeprazole in Patients With Frequent Heartburn

Father-Inclusive Parenting Intervention in Mwanza, Tanzania

Effectiveness of ResArgin on Adult's Body Composition and Health

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

OTO-313 in Subjects With Subjective Tinnitus

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

Mind-body Interventions for Healthy Aging

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease